Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NJ › Phillipsburg › NPI 1760488266
Hospital

ST. Luke's Warren Hospital, INC.

ST. Luke's Warren Hospital, INC. was paid $38.50M by Medicaid between Jan 2018 and Dec 2024, across 245 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.

33Billing provider infoST. LUKE'S WARREN HOSPITAL, INC.
PHILLIPSBURG, NJ 08865
33aNPI1760488266assigned 06/21/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$38.50M
24GClaims656,635
24DCodes billed245
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in New Jersey

Rank by total paid#41 of 93
Median peer was paid$30.60M
This provider vs. median1.3×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$250K$500K$750K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201880,411$4.65M
201982,486$4.96M
202065,961$3.59M
202186,100$4.58M
2022109,392$6.66M
2023124,464$7.73M
2024incomplete107,821$6.33M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 25% 25,538 23,501 $9.45M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 19% 18,248 16,319 $7.30M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 10% 11,252 9,913 $3.86M
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple 4.9% 1,415 1,351 $1.89M
41899 Unlisted procedure, dentoalveolar structures 4.2% 892 821 $1.61M
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete 4.0% 1,447 1,369 $1.54M
G0378 Hospital observation service, per hour 3.8% 3,714 1,963 $1.47M
99282 Emergency department visit for the evaluation and management, low to moderate severity 3.6% 6,420 6,056 $1.39M
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination 3.4% 35,250 9,497 $1.29M
97530 Therapeutic activities, direct patient contact, each 15 minutes 1.8% 13,917 5,033 $677K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) 1.5% 13,683 4,671 $574K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 1.5% 40,309 11,229 $563K
233 more codes
92507 Treatment of speech, language, voice, communication, and/or auditory processing disorder 1.3% 8,585 $498K
OP250 1.3% 47,067 $483K
74177 Computed tomography, abdomen and pelvis; with contrast material 1.2% 5,004 $457K
93017 <1% 617 $364K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 5,083 $223K
97597 <1% 1,119 $197K
41820 <1% 95 $178K
77067 Screening mammography, bilateral, including computer-aided detection <1% 2,010 $174K
45380 Colonoscopy, flexible; with biopsy, single or multiple <1% 242 $162K
96361 Intravenous infusion, hydration; each additional hour <1% 8,455 $154K
70450 Computed tomography, head or brain; without contrast material <1% 4,172 $148K
92557 <1% 451 $140K
97161 <1% 2,478 $138K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 12,555 $133K
93971 <1% 303 $132K
80053 Comprehensive metabolic panel <1% 26,186 $129K
92567 <1% 858 $107K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 1,773 $107K
96375 Therapeutic injection; each additional sequential IV push <1% 7,233 $106K
76830 Ultrasound, transvaginal <1% 1,062 $101K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 9,589 $98K
97162 <1% 1,814 $91K
71045 Radiologic examination, chest; single view <1% 8,104 $86K
71046 Radiologic examination, chest; 2 views <1% 4,040 $85K
36415 Collection of venous blood by venipuncture <1% 32,978 $83K
OP370 <1% 972 $82K
70553 Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences <1% 131 $81K
94060 <1% 126 $78K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 29,002 $78K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 4,379 $73K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 2,892 $70K
80320 <1% 1,385 $66K
77063 Screening digital breast tomosynthesis, bilateral <1% 1,716 $65K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 6,304 $59K
72125 Computed tomography, cervical spine; without contrast material <1% 1,405 $53K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 4,257 $48K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 512 $48K
71275 Computed tomographic angiography, chest, with contrast material <1% 751 $47K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 983 $46K
73630 <1% 2,632 $46K
73562 <1% 1,719 $45K
71250 <1% 494 $45K
T1015 A visit at a community health center or clinic (one all-in rate) <1% 951 $42K
73610 <1% 2,453 $41K
73030 <1% 2,057 $39K
73130 <1% 1,671 $36K
73721 Magnetic resonance imaging, any joint of lower extremity; without contrast material <1% 65 $34K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 2,409 $34K
73110 <1% 1,500 $30K
80048 Basic metabolic panel (calcium, ionized) <1% 5,577 $27K
84484 <1% 7,734 $27K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 3,733 $25K
J3490 Unclassified drugs <1% 4,020 $25K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 785 $25K
73564 <1% 1,253 $23K
97163 <1% 783 $22K
76642 <1% 387 $22K
94760 <1% 1,082 $22K
82948 <1% 4,606 $22K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm <1% 55 $21K
OP710 <1% 634 $21K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 7,218 $20K
73502 <1% 936 $20K
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 2,776 $19K
92526 <1% 338 $19K
72100 <1% 909 $18K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 5,563 $18K
83735 <1% 7,995 $16K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 69 $16K
85610 <1% 6,161 $16K
81001 <1% 9,671 $15K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 4,614 $14K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 2,688 $14K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance <1% 56 $14K
84443 Thyroid stimulating hormone (TSH) <1% 4,537 $14K
85730 <1% 5,278 $13K
85027 <1% 3,416 $13K
72148 Magnetic resonance imaging, lumbar spine; without contrast material <1% 28 $12K
G0279 Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) <1% 270 $12K
78452 Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress <1% 82 $12K
83690 <1% 7,149 $12K
81003 <1% 5,483 $11K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 889 $11K
J0690 Injection, cefazolin sodium, 500 mg <1% 1,413 $11K
70496 <1% 109 $11K
87040 <1% 1,504 $11K
74018 <1% 405 $11K
93970 <1% 12 $11K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 443 $10K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 2,742 $10K
97535 Self-care/home management training, each 15 minutes <1% 193 $10K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 408 $10K
83605 <1% 1,825 $10K
94729 <1% 83 $10K
87631 <1% 954 $10K
OP270 <1% 2,782 $9K
97116 <1% 424 $9K
94726 <1% 82 $8K
83880 <1% 2,106 $8K
73140 <1% 837 $8K
87081 <1% 647 $7K
70498 <1% 105 $7K
45385 Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) <1% 15 $6K
76536 <1% 105 $6K
87086 Culture, bacterial; quantitative colony count, urine <1% 3,243 $6K
81025 <1% 8,597 $6K
73560 <1% 323 $6K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 1,948 $6K
84702 <1% 728 $6K
96376 <1% 605 $6K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 2,489 $5K
97166 <1% 100 $5K
96367 <1% 471 $5K
80061 Lipid panel <1% 2,944 $5K
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 568 $5K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 1,055 $5K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 1,055 $5K
92587 <1% 16 $5K
87186 <1% 1,265 $5K
97164 <1% 102 $4K
87070 <1% 1,557 $4K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 8,494 $4K
J7050 Infusion, normal saline solution, 250 cc <1% 1,304 $4K
84100 <1% 1,672 $4K
73080 <1% 186 $4K
82077 <1% 2,352 $4K
87077 <1% 1,100 $4K
70486 <1% 62 $4K
86900 <1% 1,074 $3K
71271 <1% 26 $3K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 78 $3K
A9585 Injection, gadobutrol, 0.1 ml <1% 1,241 $3K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 51 $3K
C1769 Guide wire <1% 63 $3K
G1004 Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program <1% 1,843 $3K
A9270 Non-covered item or service <1% 2,399 $3K
83036 Hemoglobin; glycosylated (A1C) <1% 2,436 $3K
76770 <1% 38 $3K
J2704 Injection, propofol, 10 mg <1% 6,511 $2K
97533 <1% 97 $2K
J7030 Infusion, normal saline solution , 1000 cc <1% 5,021 $2K
80143 <1% 601 $2K
80179 <1% 550 $2K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 1,059 $2K
85379 <1% 1,857 $2K
97167 <1% 72 $2K
J2270 Injection, morphine sulfate, up to 10 mg <1% 968 $2K
G8979 Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting <1% 1,385 $2K
OP259 <1% 310 $2K
87430 <1% 790 $2K
G8978 Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals <1% 1,209 $2K
86901 <1% 1,107 $2K
87147 <1% 331 $1K
88342 <1% 350 $1K
J1756 Injection, iron sucrose, 1 mg <1% 48 $1K
J2785 Injection, regadenoson, 0.1 mg <1% 30 $1K
86803 <1% 612 $1K
80076 <1% 189 $1K
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 1,200 $1K
72110 <1% 28 $1K
87811 Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) <1% 255 $1K
77065 Tomosynthesis, mammo <1% 13 $1K
87205 <1% 428 $1K
77080 <1% 30 $1K
84145 <1% 311 $997.40
82570 <1% 704 $950.33
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 198 $879.19
90715 <1% 323 $792.47
86780 <1% 251 $788.64
82550 <1% 397 $761.26
82728 <1% 683 $759.47
84439 <1% 901 $749.32
74022 <1% 70 $736.19
J1170 Injection, hydromorphone, up to 4 mg <1% 1,721 $726.69
99213 Doctor's office visit, returning patient (routine) <1% 160 $721.10
85007 <1% 762 $715.18
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 80 $685.34
73590 <1% 40 $661.06
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 255 $544.01
10060 <1% 28 $542.80
J3475 Injection, magnesium sulfate, per 500 mg <1% 1,189 $527.55
J7120 Ringers lactate infusion, up to 1000 cc <1% 1,163 $495.21
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 1,328 $488.77
73660 <1% 12 $439.25
82607 <1% 487 $437.26
83540 <1% 695 $413.28
80329 <1% 105 $374.63
73090 <1% 13 $339.40
83550 <1% 608 $287.27
86850 <1% 428 $286.47
73100 <1% 14 $271.07
C9113 Injection, pantoprazole sodium, per vial <1% 360 $267.30
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 499 $259.03
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 431 $238.39
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 386 $210.12
87400 <1% 145 $189.79
86140 <1% 605 $169.36
J1650 Injection, enoxaparin sodium, 10 mg <1% 208 $169.34
85652 <1% 651 $127.81
A9502 Technetium tc-99m tetrofosmin, diagnostic, per study dose <1% 57 $118.39
82043 <1% 260 $104.02
29125 <1% 12 $100.03
84703 <1% 194 $98.20
J0737 Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg <1% 193 $97.73
G8980 Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting <1% 107 $94.91
82746 <1% 120 $93.69
86618 <1% 67 $79.89
82805 <1% 54 $75.92
J2919 Injection, methylprednisolone sodium succinate, 5 mg <1% 105 $57.72
83970 <1% 32 $56.59
72020 <1% 222 $53.56
87807 <1% 64 $53.18
J2060 Injection, lorazepam, 2 mg <1% 465 $44.07
87340 <1% 47 $36.00
J1644 Injection, heparin sodium, per 1000 units <1% 120 $28.96
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 419 $28.90
J1171 Injection, hydromorphone, 0.1 mg <1% 36 $21.78
Q9966 Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml <1% 920 $21.32
J0330 Injection, succinylcholine chloride, up to 20 mg <1% 14 $18.86
J1040 Injection, methylprednisolone acetate, 80 mg <1% 284 $14.59
J2003 Injection, lidocaine hydrochloride, 1 mg <1% 178 $12.80
J1596 Injection, glycopyrrolate, 0.1 mg <1% 60 $11.60
84156 <1% 16 $8.70
J2470 Injection, pantoprazole sodium, 40 mg <1% 31 $2.37
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg <1% 17 $1.00
J1010 Injection, methylprednisolone acetate, 1 mg 0% 75 $0.00
J0696 Injection, ceftriaxone sodium, per 250 mg 0% 26 $0.00
G8982 Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 0% 105 $0.00
G8981 Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals 0% 47 $0.00
86308 0% 15 $0.00
12001 0% 14 $0.00
G8984 Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals 0% 375 $0.00
G8985 Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 0% 444 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialALBERTO, CARL (VICE PRESIDENT OF FINANCE)